Dr Elizabeth McArdle
Telephone

Dr Elizabeth McArdle
National Decommissioning Centre Manager
- About
-
National Decommissioning Centre
Main Street, Newburgh
Aberdeenshire
AB41 6AA
01224 274403
Biography
Accrediation (2018) ILM Level 3 Leadership and Management
Manager of the National Decommissioning Centre (NDC) since April 2019. The NDC is a £38M partnership between the University of Aberdeen and the Oil and Gas Technology Centre (OGTC), supported by the Aberdeen City Regional Deal. Launched in January 2019, the NDC works in partnership with industry, government and research organisations to deliver high-impact multi-disciplinary research and training that will transform the decommissioning sector with a focus on energy transition that aligns with the Scottish and UK Government’s net zero emissions targets.
July 2016 - March 2019 - Manager of the Medical Research Council Centre of Medical Mycology (MRC CMM), a £6.5M initiative between the Medical Research Council (MRC) and University of Aberdeen. The MRC CMM is one of only 22 MRC centre in the UK.
May 2012 - June 2016 - Manager of the £5.1M Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology at the University of Aberdeen.
May 2006 - December 2011 - Business Development Officer, Research and Innovation, University of Aberdeen. Supported the School of Biological Sciences, Institute of Biological and Environmental Sciences (IBES) and School of Paychology, comprising 86 academic staff, 101 post doctorates and 207 PhD students and total active research awards of £20M.
March 2004 - May 2006 - Research Fellow - Awarded a Scottish Hospitals Endowment Research Trust (SHERT) New Investigator grant worth £80K.
Nov 1999 to March 2004 - PhD in Medicine and Therapeutics, University of Aberdeen
August 1998 - Nov 1999 - Team Leader – SmithKline Beecham Pharmaceuticals (GlaxoSmithkline), Ayrshire, Scotland
Managed a team of analytical chemists and technicians working on continuous improvement initiatives in the QA department. Supported technology transfer of new drugs and technologies from R&D.